Ontology highlight
ABSTRACT: Importance
Little is known about how out-of-pocket burden differs between Medicare and commercial insurance for ultra-expensive drugs.Objective
To investigate out-of-pocket spending for ultra-expensive drugs in the Medicare Part D program vs commercial insurance.Design, setting, and participants
This was a retrospective, population-based cohort study of individuals using ultra-expensive drugs included in a 20% nationally random sample of prescription drug claims from Medicare Part D and individuals aged 45 to 64 years using ultra-expensive drugs included in a large national convenience sample of outpatient pharmaceutical claims from commercial insurance plans. Claims data from 2013 through 2019 were used, and data were analyzed in February 2023.Main outcomes and
SUBMITTER: DiStefano MJ
PROVIDER: S-EPMC10220512 | biostudies-literature | 2023 May
REPOSITORIES: biostudies-literature